Results 141 to 150 of about 208,148 (266)
Targeting self-renewal pathways in myeloid malignancies [PDF]
, 2013 A fundamental property of hematopoietic stem cells (HSCs) is the ability to self-renew. This is a complex process involving multiple signal transduction cascades which control the fine balance between self-renewal and differentiation through ...
Copland, M., Sands, W.A., Wheadon, H.
core +2 more sources
Autopsy and Case Reports, 2021 Myeloid sarcoma (MS) is a rare extramedullary neoplasm of myeloid cells, which can arise before, concurrently with, or following hematolymphoid malignancies.
Toyaja Jadhav +2 more
doaj
Revista Brasileira de Hematologia e Hemoterapia, 2012 OBJECTIVE: This study aimed to verify the association between human leukocyte antigens and the bcr-abl fusion protein resulting from t(9;22)(q34;q11) in chronic leukemia myeloid and acute lymphoblastic leukemia patients.
Daiana Landenberger de Carvalho +3 more
doaj +1 more source
IRE1 alpha may be causing abnormal loss of p53 at post transcriptional level in chronic myeloid leukemia [PDF]
arXiv, 2017 Current treatment strategy for chronic myeloid leukemia (CML) mainly includes inhibition of tyrosine kinase activity, which has dramatically improved the prognosis of the disease but without cure. In addition some patients may become drug resistant. Thus there is still the need for other therapies to avoid resistance and if possible to cure the disease.
arxiv
Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells [PDF]
, 2015 SummaryLeukemic cells disrupt normal patterns of blood cell formation, but little is understood about the mechanism. We investigated whether leukemic cells alter functions of normal hematopoietic stem and progenitor cells. Exposure to chronic myelogenous
Amabile, Giovanni +11 more
core +1 more source
Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update [PDF]
, 2018 Despite considerable progress in treatment protocols, B-lineage acute lymphoblastic leukemia (B-ALL) displays a poor prognosis in about 15–20% of pediatric cases and about 60% of adult patients. In addition, life-long irreversible late effects from chemo-
Capitani, Silvano +6 more
core +1 more source
Biomédica: revista del Instituto Nacional de Salud, 2014 Introducción. Los nuevos inhibidores de la tirosina cinasa para tratar la leucemia mieloide crónica basados en nilotinib, dasatinib e imatinib, mejoraron la calidad de vida de los pacientes y la tornaron en enfermedad crónica. Objetivo. Evaluar el costo-
Martín Romero +3 more
doaj +1 more source
Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia [PDF]
Oncotarget, Impact journals, 2018, 2019 Background: Chronic myeloid leukemia (CML) results from hematopoietic stem cell transformation by the bcr-abl chimeric oncogene, encoding a 210 kDa protein with constitutive tyrosine kinase activity. In spite of the efficiency of tyrosine kinase inhibitors (TKI; Imatinib), other strategies are explored to eliminate CML leukemia stem cells, such as ...
arxiv
Combined population dynamics and entropy modelling supports patient stratification in chronic myeloid leukemia [PDF]
, 2016 Modelling the parameters of multistep carcinogenesis is key for a better understanding of cancer progression, biomarker identification and the design of individualized therapies.
Brehme, Marc +7 more
core +1 more source
Dasatinib: ten years of clinical practice worldwide
Онкогематология, 2016 The article contains results of meta-analysis of experience in use of second-generation tyrosine kinase inhibitors – dasatinib. The results of clinical trials dasatinib therapy in chronic myelogenous leukemia imatinib-resistant or intolerant patients are
K. M. Abdulkadyrov +2 more
doaj +1 more source